Pregabalin Capsule
Product Images NDC 71610-996

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-996). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 996 30)

Pregabalin 300 mg oral capsules packaging label showing product name, strength, quantity of 30 capsules, and NDC 71610-996-30. Label includes storage instructions, manufacturer SciGen Pharmaceuticals Inc, and packager Aphena Pharma, Cookeville, TN.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin doses and placebo. Four lines represent Pregabalin 200 mg three times a day, 100 mg three times a day, 25 mg three times a day, and placebo, illustrating patient improvement across increasing pain relief percentages.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line chart comparing the percent of patients improved versus percent improvement in pain from baseline between two groups: Pregabalin 100 mg three times a day and placebo. The vertical axis represents percent of patients improved, and the horizontal axis shows percent improvement in pain from baseline, with curves indicating greater improvement for the Pregabalin group.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph comparing percent improvement in pain from baseline on the x-axis with percent of patients improved on the y-axis. It shows curves for Pregabalin 300 mg, 150 mg, 75 mg dosed twice daily, and placebo, illustrating differences in patient response at various improvement thresholds.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph showing the percent of patients improved plotted against percent improvement in pain from baseline. Three lines represent Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph depicts higher percentages of patient improvement for the Pregabalin doses compared to placebo across increasing pain improvement percentages.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph showing percent of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. Lines indicate patient improvement percentages across increasing pain improvement thresholds ranging from greater than 0 to 100 percent.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart comparing responder rates (%) across different dosing regimens of pregabalin in two studies labeled E1 and E3. The x-axis shows treatment groups, including placebo and varying daily doses, while the y-axis shows responder rates from 0% to 60%. Statistically significant increases versus placebo are marked with an asterisk.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph depicting seizure reduction (median percentage change from baseline) versus dose (mg/day) in several studies labeled E1, E2, and E3 with BD and TID dosing schedules. The graph shows dose-dependent increases in seizure reduction with accompanying p-values indicating statistical significance.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph comparing the percent of patients improved against the percent improvement in pain from baseline for Pregabalin at daily doses of 300 mg, 450 mg, and 800 mg, alongside placebo. The graph includes four lines, each representing one treatment group, showing relative effectiveness across different improvement percentages in pain.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A Kaplan-Meier survival curve showing the estimated percentage of subjects without LTR over 180 days comparing Pregabalin and Placebo groups. The y-axis represents the estimated percentage of subjects without LTR, ranging from 0% to 100%, and the x-axis indicates days from 0 to 180. The Pregabalin group is represented by a solid line, while the Placebo group is shown with a dashed line.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A chart showing the percent of subjects improved over different percentage improvement thresholds from baseline to week 12 for Pregabalin versus placebo. The x-axis represents percent improvement from baseline and the y-axis represents the percent of subjects improved. Two lines are shown: a solid line for Pregabalin and a dashed line for placebo, indicating higher improvement rates with Pregabalin.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percentage of subjects improved on the vertical axis against percent improvement from baseline to Week 16 BOCF on the horizontal axis. Two lines represent Pregabalin and Placebo, with Pregabalin showing higher improvement percentages across the range. The graph highlights differences in subject improvement between Pregabalin and Placebo treatments over the specified period.*

FDA Label Image

Figure 13 (Pregabalin Fig13)

A vertical bar chart showing responder rates (%) for Pregabalin at 2.5 mg/kg/day and 10 mg/kg/day doses compared with a placebo group. The x-axis categories are Placebo (93 subjects), 2.5 mg/kg/day (103 subjects), and 10 mg/kg/day (96 subjects). The y-axis represents responder rates in percentages, with values shown above each bar: 22.6% for placebo, 29.1% for 2.5 mg/kg/day, and 40.6% for 10 mg/kg/day.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

The image shows a text formula calculating creatinine clearance (CLcr) based on age in years, weight in kilograms, and serum creatinine in mg/dL, including a multiplication factor of 0.85 for female patients.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of pregabalin showing the arrangement of atoms including a carboxylic acid group, an amine group, and a branched carbon chain. This diagram represents the active ingredient pregabalin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.